
OBJECTIVE Hyperspectral imaging (HSI) is a label-free optical technique that might extend conventional intraoperative visualization by providing quantitative spectral information from the operative field. The aim of this study was to evaluate whether intraoperative in vivo HSI combined with machine learning (ML)–based analysis can distinguish cranial meningioma from adjacent intracranial tissues, particularly cortex and dura, during meningioma surgery. METHODS This interim analysis of an ongoing prospective observational study included patients who underwent elective cranial meningioma surgery at a single tertiary neurosurgical center. Intraoperative HSI was performed using a CE-marked tissue system at predefined surgical time points. Expert-defined regions of interest (ROIs) representing meningioma, cortex, and dura were annotated on HSI-derived RGB images. Pixel-wise reflectance spectra were extracted and analyzed as raw reflectance spectra, standard normal variate–normalized spectra, and first- and second-derivative spectra. Four ML classifiers, including linear discriminant analysis, support vector machine, logistic regression, and multilayer perceptron, were evaluated using leave-one-patient-out cross-validation. Two classification tasks were investigated: binary discrimination of meningioma versus cortex, and multiclass discrimination of meningioma, cortex, and dura. RESULTS Among 70 patients, 291,104 meningioma pixels from 248 ROIs, 141,515 cortex pixels from 135 ROIs, and 333,244 dura pixels from 104 ROIs were analyzed. Meningioma showed distinct spectral characteristics, including attenuation of the oxyhemoglobin-associated double peak and lower tissue oxygenation, compared with cortex and dura. For binary classification of meningioma versus cortex, the multilayer perceptron using standard normal variate–normalized spectra achieved the highest performance, with an accuracy of 0.928, precision of 0.960, recall of 0.932, F1 score of 0.946, weighted F1 score of 0.929, and Matthews correlation coefficient of 0.840. In the multiclass task, performance was lower but remained feasible, with the same classifier-preprocessing combination achieving an accuracy of 0.773, macro F1 score of 0.782, weighted F1 score of 0.772, and macro Matthews correlation coefficient of 0.662. CONCLUSIONS ML-assisted intraoperative HSI enabled feasible discrimination of expert-annotated meningioma, cortex, and dura regions in cranial meningioma surgery. These interim findings support HSI as a promising label-free optical guidance technology, while underscoring the need for external validation, patient-level analyses, WHO grade prediction, and spatially matched histopathological confirmation before clinical implementation.
The 2021 WHO CNS tumor classification marked a fundamental shift in neuro-oncology: molecular markers rather than histological appearance now define glioma diagnosis and guide treatment. Yet, in clinical practice the molecular information that matters most to a surgeon—IDH status, 1p/19q codeletion, and methylation class—typically arrives days to weeks after the operation it was meant to inform. Artificial intelligence (AI) is beginning to close that gap. Over the past several years, a growing body of work has demonstrated that AI models can extract diagnostically relevant molecular and histological information from data sources available in the operating room, in real time, at the point of surgical decision-making. In this review, the authors provide a comprehensive overview of state-of-the-art intraoperative AI models available to neurosurgeons during brain tumor resections. They examine AI-augmented approaches to established intraoperative techniques, such as cryosection and fluorescence-guided surgery, before turning to novel technologies including nanopore sequencing and stimulated Raman histology (SRH). The authors conclude by discussing barriers to widespread clinical adoption and what lies ahead for this field. For cryosection, models such as LGNet and the Cryosection Histopathology Assessment and Review Machine (CHARM) have demonstrated strong performance on intraoperative discrimination of primary CNS lymphoma and molecular subtyping of glioma, respectively, with CHARM achieving areas under the receiver operating characteristic curve of 0.88–0.93 across glioma subtypes. In fluorescence-guided surgery, hyperspectral imaging combined with machine learning has enabled classification of tumor type, grade, and IDH mutation based on the 5-aminolevulinic acid (5-ALA) signal with up to 93% accuracy, extracting molecular information from a modality already present in the operating room. For nanopore-based methylation classification, ensemble models such as Rapid Nanopore Brain Intraoperative Classification (ROBIN) have achieved 90% concordance with the final diagnosis prospectively in under 2 hours. In SRH, foundation models for infiltration detection now outperform FLAIR, contrast enhancement, and 5-ALA fluorescence in identifying tumor margins, while molecular classification models have achieved over 90% glioma subtype accuracy in multi-institutional cohorts. At the single-cell level, morphometric profiling of SRH images has revealed nuclear features distinguishing IDH-mutant from IDH-wildtype tumors, opening new avenues for interpretability. Despite this progress, widespread adoption remains limited by the absence of randomized clinical trials demonstrating patient-level benefit. Addressing this gap and realizing the potential of multimodal AI systems that integrate imaging, pathology, and molecular data represent critical next steps for the field.
OBJECTIVE In this study, the authors aimed to characterize trends in the regulatory authorization of spine surgery devices in the United States, including device category composition, regulatory pathway use, decision timelines, and patterns of new market entry. METHODS Authorizations related to spine surgery issued between January 1, 2000, and December 31, 2023, were identified from the publicly available US Food and Drug Administration (FDA) 510(k), Premarket Approval (PMA), De Novo, and Humanitarian Device Exemption databases and classified into one of 7 categories (spinal implants and fixation, navigation, bone graft and augmentation, surgical instruments, neuromodulation and nerve, measurement and diagnostics, and other) according to intended use. Annual authorization volume, regulatory pathway, decision time, device class, sponsor experience, and manufacturer location were extracted, and category-level trends were evaluated using 3-year trailing averages. Group comparisons were performed using one-way ANOVA and Welch’s t-test. RESULTS A total of 5977 spine devices were authorized over the study period. Spinal implants and fixation accounted for most devices (n = 4328, 72.4%), followed by navigation (n = 753, 12.6%). Annual authorization volume more than doubled from 108 devices in 2000 to 342 in 2023. During the same period, the proportional share represented by spinal implants and fixation declined from 78.7% to 50.9%, while navigation increased from 0% to 31.3%, reaching 107 authorizations by 2023 and emerging as the second-largest spine category. The 510(k) pathway accounted for 99.4% of all authorizations. Special 510(k) submissions cleared faster than traditional submissions (59.1 vs 144.0 days), and Class III and PMA submissions required the longest review (530.0 and 613.8 days, respectively; all p < 0.001). Established sponsors and domestic manufacturers demonstrated shorter times to authorization than emerging and international counterparts (both p < 0.001). New market entries were concentrated in spinal implants and fixation (n = 1529) and bone graft and augmentation (n = 399). CONCLUSIONS The US spine device landscape has evolved from one dominated by implant and fixation hardware to a more diverse ecosystem defined by navigation, bone graft and augmentation, and other adjunctive technologies, which together now account for nearly half of annual FDA authorizations. Regulatory pathway, device class, sponsor experience, and manufacturer location were each associated with time to FDA decision. These findings provide spine surgeons, innovators, and regulators with a contemporary view of how spine technologies enter clinical practice and highlight areas that may warrant surveillance, particularly in incumbent-dominated categories.